


Reference Data (FY2005)



Daiichi-Sankyo

DAIICHISANKYO CO., LTD.

[http:// www.daiichisankyo. co.jp](http://www.daiichisankyo.co.jp)

Unit shareholders; Holders of trading lots of shares

	As of March 2006			As of March 2005		
	Number of Shareholders	Number of shares (million)	%	Number of Shareholders	Number of shares (million)	%
Government and Public	1	0	0.0%	1	0	0.0%
Sankyo G				1	0	0.0%
Daiichi G				0	0	0.0%
Financial institutions	185	304	42.9%	243	299	41.3%
Sankyo G				146	189	43.1%
Daiichi G				97	110	38.7%
Securities Companies	44	7	3.8%	65	13	1.8%
Sankyo G				40	8	1.9%
Daiichi G				25	5	1.8%
Corporate investors	635	49	6.7%	710	49	6.9%
Sankyo G				410	25	5.9%
Daiichi G				300	23	8.4%
Foreign investors	569	236	32.8%	872	239	33.0%
Sankyo G				521	143	32.7%
Daiichi G				351	95	33.4%
Individuals	55,244	99	13.9%	50,661	95	13.1%
Sankyo G				34,548	62	14.2%
Daiichi G				16,113	32	11.5%
Treasury stock	1	0	0.0%	2	28	3.9%
Sankyo G				1	9	2.3%
Daiichi G				1	18	6.3%
Total	56,679	733	100.0%	52,554	724	100.0%

※The number of shares held as of September 30, 2005, is a simple total of the number of trading lots held by both companies on the date of transfer (Sept. 27) multiplied by the transfer ratio; the number of shares held as of March 31, 2005, is a simple total of the number of trading lots held by both companies on March 31. The number of shareholders is a simple total of all holders of stock in both companies.

<Prospective>

Dividend for year	60 yen
Dividend payout ratio	93.1% (Consolidated)
Dividend on equity ratio (DOE)	3.5%

Difference from estimate

FY2004								
	Net sales		Operating income		Ordinary income		Net income	
	million yen	change	million yen	change	million yen	change	million yen	change
1st half	449,127	—	74,178	—	76,248	—	48,727	—
Sankyo Group	289,988	▲2.2%	49,159	▲3.7%	50,073	▲1.0%	37,965	59.3%
Daiichi Group	159,139	▲2.0%	25,019	▲5.4%	26,175	▲1.5%	10,762	▲29.7%
DAIICHI SANKYO non-consolidated	—	—	—	—	—	—	—	—
2nd half	467,236	—	66,809	—	63,578	—	36,729	—
Sankyo Group	297,842	▲0.7%	35,766	▲19.6%	32,433	▲25.3%	10,317	▲47.3%
Daiichi Group	169,394	5.6%	31,043	57.8%	31,145	54.5%	26,412	132.7%
DAIICHI SANKYO non-consolidated	—	—	—	—	—	—	—	—
Full Year	916,364	—	140,988	—	139,826	—	85,457	—
Sankyo Group	587,830	▲1.4%	84,925	▲11.1%	82,506	▲12.2%	48,282	11.2%
Daiichi Group	328,534	1.8%	56,063	21.6%	57,320	22.7%	37,175	39.4%
DAIICHI SANKYO non-consolidated	—	—	—	—	—	—	—	—

FY2005 Estimate (November)								
	Net sales		Operating income		Ordinary income		Net income	
	million yen	change	million yen	change	million yen	change	million yen	change
1st half	451,808	0.6%	80,345	8.3%	82,642	8.4%	49,450	1.5%
Sankyo Group	286,207	▲1.3%	48,101	▲2.2%	49,899	▲0.3%	31,953	▲15.8%
Daiichi Group	165,667	4.1%	31,809	27.1%	32,818	25.4%	17,594	63.5%
DAIICHI SANKYO non-consolidated	816	—	400	—	39	—	23	—
2nd half	448,192	▲4.1%	46,655	▲30.2%	47,358	▲25.5%	21,550	▲41.3%
Sankyo Group	278,793	▲6.4%	19,899	▲44.4%	20,101	▲38.0%	9,047	▲12.3%
Daiichi Group	169,333	▲0.0%	27,191	▲12.4%	27,182	▲12.7%	15,406	▲41.7%
DAIICHI SANKYO non-consolidated	77,184	—	73,600	—	73,961	—	73,977	—
Full Year	900,000	▲1.8%	127,000	▲9.9%	130,000	▲7.0%	71,000	▲16.9%
Sankyo Group	565,000	▲3.9%	68,000	▲19.9%	70,000	▲15.2%	41,000	▲15.1%
Daiichi Group	335,000	2.0%	59,000	5.2%	60,000	4.7%	33,000	▲11.2%
DAIICHI SANKYO non-consolidated	78,000	—	74,000	—	74,000	—	74,000	—

FY2005 Results								
	Net sales		Operating income		Ordinary income		Net income	
	million yen	change	million yen	change	million yen	change	million yen	change
1st half	451,808	0.6%	80,345	8.3%	82,642	8.4%	49,450	1.5%
Sankyo Group	286,207	▲1.3%	48,101	▲2.2%	49,899	▲0.3%	31,953	▲15.8%
Daiichi Group	165,667	4.1%	31,809	27.1%	32,818	25.4%	17,594	63.5%
DAIICHI SANKYO non-consolidated	816	—	400	—	39	—	23	—
2nd half	474,110	1.5%	74,383	11.3%	77,072	21.2%	38,242	4.1%
Sankyo Group	293,742	▲1.4%	30,234	▲15.5%	32,265	▲0.5%	18,674	81.0%
Daiichi Group	180,780	6.7%	44,278	42.6%	45,111	44.8%	19,815	▲25.0%
DAIICHI SANKYO non-consolidated	75,840	—	73,548	—	73,552	—	73,522	—
Full Year	925,918	1.0%	154,728	9.7%	159,714	14.2%	87,692	2.6%
Difference from estimate	25,918		27,728		29,714		16,692	
increase/decrease vs.FY04	9,554		13,740		19,888		2,235	
Sankyo Group (Nov.)	579,949	▲1.3%	78,335	▲7.8%	82,164	▲0.4%	50,627	4.9%
Difference from estimate	14,949		10,335		12,164		9,627	
increase/decrease vs.FY04	▲7,881		▲6,590		▲342		2,345	
Daiichi Group (Nov.)	346,447	5.5%	76,087	35.7%	77,929	36.0%	37,409	0.6%
Difference from estimate	11,447		17,087		17,929		4,409	
increase/decrease vs.FY04	17,913		20,024		20,609		234	
DAIICHI SANKYO non-consolidated	76,656	—	73,948	—	73,591	—	73,545	—
Difference from estimate	▲1,344		▲52		▲409		▲455	
increase/decrease vs.FY04	—		—		—		—	

Estimate

FY2006 Estimate								
	Net sales		Operating income		Ordinary income		Net income	
	million yen	change	million yen	change	million yen	change	million yen	change
1st half(Estimate)	470,000	4.0%	55,000	▲31.5%	60,000	▲27.4%	38,000	▲23.2%
2nd half(Estimate)	395,000	▲16.7%	53,000	▲28.7%	55,000	▲28.6%	9,000	▲76.5%
Full Year (Estimate)	865,000	▲6.6%	108,000	▲30.2%	115,000	▲28.0%	47,000	▲46.4%
increase/decrease vs. FY05	▲60,918		▲46,728		▲44,714		▲40,692	

Progress of Statement

	FY2004			FY2005 Results						FY2006 (Estimate)	
	Full year			1st half			Full year			DAIICHISANKYO	
	Total	Sankyo	Daiichi	DS*	Sankyo Group	Daiichi Group	DS	Sankyo Group	Daiichi Group	1st half	Full year
Change	<-0.3>	<-1.4>	<1.8>	<0.6>	<-1.3>	<4.1>	<1.0>	<-1.3>	<5.5>	<4.0>	<-6.6>
Net sales	916,364	587,830	328,534	451,808	286,207	165,667	925,918	579,949	346,447	470,000	865,000
Cost of Sales	314,723	213,889	100,834	141,296	94,770	46,527	290,735	198,263	92,190	133,400	234,200
Cost of Sales ratio	34.3%	36.4%	30.7%	31.3%	33.1%	28.1%	31.4%	34.2%	26.6%	28.4%	27.1%
Selling, General and Administrative	460,651	289,015	171,636	230,166	143,336	87,330	480,454	303,350	178,169	281,600	522,800
SAGA ratio	50.3%	49.2%	52.2%	50.9%	50.1%	52.7%	51.9%	52.3%	51.4%	59.9%	60.4%
R&D expenses	145,200	86,551	57,416	72,528	42,596	30,031	158,716	97,265	61,647	87,000	167,000
R&D expenses ratio	15.8%	14.7%	17.5%	16.1%	14.9%	18.1%	17.1%	16.8%	17.8%	18.5%	19.3%
Change	<-0.5>	<-11.1>	<21.6>	<8.3>	<-2.2>	<27.1>	<9.7>	<-7.8>	<35.7>	<-31.5>	<-30.2>
Operating income	140,988	84,925	56,063	80,345	48,101	31,809	154,728	78,335	76,087	55,000	108,000
/Net sales	15.4%	14.4%	17.1%	17.8%	16.8%	19.2%	16.7%	13.5%	22.0%	11.7%	12.5%
Change	<-0.6>	<-12.2>	<22.7>	<8.4>	<-0.3>	<25.4>	<14.2>	<-0.4>	<36.0>	<-27.4>	<-28.0>
Ordinary income	139,826	82,506	57,320	82,642	49,899	32,818	159,714	82,164	77,929	60,000	115,000
/Net sales	15.3%	14.0%	17.4%	18.3%	17.4%	19.8%	17.2%	14.1%	22.5%	12.8%	13.3%
Change	<22.0>	<-31.0>	<39.4>	<1.5>	<-15.8>	<63.5>	<2.6>	<4.9>	<0.6>	<-23.2>	<-46.4>
Net income	85,457	48,282	37,175	49,450	31,953	17,594	87,692	50,627	37,409	38,000	47,000
/Net sales	9.3%	8.2%	11.3%	10.9%	11.2%	10.6%	9.5%	8.7%	10.8%	8.1%	5.4%

*DAIICHI SANKYO

Ratio of consolidated

		FY2004	FY2005		
			1st half	Estimate(Nov.)	Full year
Net sales	Sankyo G	1.73	1.75	1.83	1.82
	Daiichi G	1.26	1.25	1.25	1.25
Operating income	Sankyo G	1.32	1.43	1.48	1.69
	Daiichi G	1.03	1.08	1.04	1.07
Ordinary income	Sankyo G	1.29	1.42	1.49	1.68
	Daiichi G	1.02	1.05	1.00	1.05
Net income	Sankyo G	1.29	1.78	1.86	2.19
	Daiichi G	1.93	2.36	1.50	1.20

Business Performance

million yen

	FY2004		FY2005			FY2006 Estimate	
	1st half	Full year	1st half	Full year		1st half	Full year
				Estimate (Nov.)	Results		
Overseas sales	142,700	284,200	153,600	292,500	307,200	176,300	319,000
Sankyo Group	109,200	215,600	—	—	—	—	—
Daiichi Pharmaceuticals	33,500	68,600	—	—	—	—	—
Overseas/ Net sales	31.8%	31.0%	34.0%	32.5%	33.2%	37.5%	36.9%
Sankyo Group	37.6%	36.7%	—	—	—	—	—
Daiichi Pharmaceuticals	21.1%	20.9%	—	—	—	—	—
Capital expenditure	22,100	42,200	17,800	—	30,100	13,650	27,300
Sankyo Group	16,300	30,000	—	—	—	—	—
Daiichi Pharmaceuticals	5,800	12,200	—	—	—	—	—
Depreciation expense	21,200	44,700	19,500	40,500	44,400	17,800	35,200
Sankyo Group	13,900	28,800	—	—	—	—	—
Daiichi Pharmaceuticals	7,300	15,900	—	—	—	—	—

	FY2004		FY2005		FY2006 Estimate
	1st half	Full year	1st half	Full year	
Dividend on equity ratio (D O E)	—	—	1.5%	2.9%	3.5%
Sankyo Group	0.9%	2.4%	-	-	-
Daiichi Pharmaceuticals	0.9%	2.4%	-	-	-
Dividend payout ratio	—	—	34.7%	40.5%	93.1%
Sankyo Group	17.0%	35.8%	-	-	-
Daiichi Pharmaceuticals	37.4%	29.0%	-	-	-
Return on equity (R O E)	—	—	4.2%	7.3%	3.8%
Sankyo Group	5.5%	6.9%	-	-	-
Daiichi Pharmaceuticals	2.5%	8.5%	-	-	-
Earnings per share (E P S)	—	—	67.5yen	119.4yen	64.5 yen
Sankyo Group	88.4yen	111.8yen	-	-	-
Daiichi Pharmaceuticals	40.1yen	138.0yen	-	-	-
Shareholder's equity ratio	—	—	77.3%	77.5%	
Sankyo Group	74.5%	73.4%	-	-	
Daiichi Pharmaceuticals	81.1%	82.1%	-	-	
Book value per share (B P S)	—	—	1,610.6yen	1,696.9yen	
Sankyo Group	1,647.7yen	1,667.8yen	-	-	
Daiichi Pharmaceuticals	1,582.7yen	1,670.7yen	-	-	
Number of consolidated subsidiaries	—	—	61	57	
Sankyo Group	37	37	-	-	
Daiichi Pharmaceuticals	31	31	-	-	
Number of employees	19,016	18,777	18,648	18,434	
Sankyo Group	11,577	11,444	-	-	
Daiichi Pharmaceuticals	7,439	7,333	-	-	

Consolidated Segment information - Business

million yen

		FY2004			FY2005					
		1st half	2nd half	Full year	1st half		2nd half		Full year	
						Change		Change		Change
	Domestic	212,904	220,480	433,384	208,266	▲4,638	223,135	+2,655	431,401	▲1,983
	Overseas	133,269	132,213	265,482	145,253	+11,984	144,277	+12,064	289,530	+24,048
	OTC drugs	15,577	14,056	29,633	14,794	▲783	13,106	▲950	27,900	▲1,733
Pharmaceuticals		378,889	387,666	766,555	385,415	+6,526	399,251	+11,585	784,666	+18,111
Other		70,237	79,572	149,809	66,393	▲3,844	74,858	▲4,714	141,251	▲8,558
Consolidated Sales		449,127	467,237	916,364	451,808	+2,681	474,110	+6,873	925,918	+9,554
Pharmaceuticals		75,562	66,029	141,591	77,651	+2,089	70,463	+4,434	148,114	+6,523
Other		1,926	4,583	6,509	2,321	+395	3,825	▲758	6,146	▲363
Consolidated Operating income		74,178	66,810	140,988	80,345	+6,167	74,383	+7,573	154,728	+13,740

Segment information - Area

million yen

		FY2004			FY2005					
		1st half	2nd half	Full year	1st half		2nd half		Full year	
						Change		Change		Change
	Japan	380,866	390,158	771,024	371,239	▲9,627	381,554	▲8,604	752,793	▲18,231
	North America	42,188	45,661	87,849	53,741	+11,553	62,320	+16,659	116,061	+28,212
	Other	26,071	31,419	57,490	26,827	+756	30,236	▲1,183	57,063	▲427
Consolidated Sales		449,127	467,237	916,364	451,808	+2,681	474,110	+6,873	925,918	+9,554
Japan		69,675	59,838	129,513	69,124	▲551	61,125	+1,287	130,249	+736
North America		6,753	5,575	12,328	11,916	+5,163	13,541	+7,966	25,457	+13,129
Other		▲2,522	1,671	▲851	△1,451	1,071	1,629	▲42	178	+1,029
Consolidated Operating income		74,178	66,810	140,988	80,345	+6,167	74,383	+7,573	154,728	+13,740

Segment Information (Reference)

million yen

			FY2006 Estimate					
			1st half		2nd half		Full year	
				Change		Change		Change
Pharmaceuticals	Domestic (Sankyo,Daiichi Pharmaceuticals non-consolidated)		202,400	—	212,100	—	414,500	—
	US	Exports	21,000	—	22,800	—	43,800	—
		DSI*	69,700	—	52,000	—	121,700	—
		LPI**	30,600	—	16,300	—	46,900	—
	Europe	Exports	12,900	—	10,000	—	22,900	—
		SPG***	25,800	—	23,800	—	49,600	—
	DAIICHI SANKYO HEALTHCARE CO., LTD. ZEPHARMA		26,000	—	28,200	—	54,200	—
	Other Company (Total)		25,600	—	27,800	—	53,400	—
Other		56,000	—	2,000	—	58,000	—	
Consolidated Sales			470,000	—	395,000	—	865,000	—

* The American subsidiaries of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd. was integrated on March 2005. The newly formed company commenced business on April 3, 2006, under the name, DAIICHI SANKYO, INC. (DSI). Accounting term of overseas subsidiaries(DSI,LPI) is 15-month fiscal year (Jan. 2006 to Mar.2007) from accounting change.

** DSI and LPI have 15-month fiscal term.

***Sales of Sales Division

			FY2006 Estimate					
			1st half		2nd half		Full year	
				Change		Change		Change
Pharmaceuticals	Domestic sales/Exports (Sankyo,Daiichi Pharmaceuticals non-consolidated)		31,800	—	43,100	—	74,900	—
	US	DSI*	14,400	—	10,400	—	24,800	—
		LPI**	13,000	—	4,500	—	17,500	—
	Europe	SPG***	3,300	—	700	—	4,000	—
	Other Comapany Eliminations		▲ 10,700	—	▲ 6,500	—	▲ 17,200	—
Other		3,200	—	800	—	4,000	—	
Consolidated Operating income			55,000	—	53,000	—	108,000	—

* The American subsidiaries of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd. was integrated on March 2005. The newly formed company commenced business on April 3, 2006, under the name, DAIICHI SANKYO, INC. (DSI). Accounting term of overseas subsidiaries(DSI,LPI) is 15-month fiscal year (Jan. 2006 to Mar.2007) from accounting change.

** DSI and LPI have 15-month fiscal term.

***Operating income of Sales Division

Main Prescription drug sales[Results]

Million yen

			*	FY2004			FY2005					
				1st half	2nd half	Full Year	Estimate (November 2005)	1st half	2nd half	Full Year		
										Difference from estimate	Change	
Japan	Cardiovascular	Mevalotin	S	42,600	39,900	82,500	75,900	38,500	36,700	75,200	▲700	▲8.8%
		Panaldine	D	14,900	13,700	28,600	28,100	14,700	13,600	28,300	+200	▲1.0%
		Artist	D	7,700	7,900	15,600	18,100	9,100	9,100	18,200	+100	16.7%
		Sunrhythm	D	5,600	5,500	11,100	11,900	6,000	5,900	11,900	+0	7.2%
		Acecol	S	5,800	5,100	10,900	9,100	4,800	4,300	9,100	+0	▲16.5%
		Olmotec	S	4,500	4,500	9,000	24,000	10,000	15,600	25,600	+1,600	184.4%
		Coversyl	D	4,500	4,200	8,700	8,800	4,500	3,900	8,400	▲400	▲3.4%
		Hanp	D	3,000	4,000	7,000	8,700	3,900	4,700	8,600	▲100	22.9%
		Calblock	S	1,200	1,800	3,000	7,100	3,000	3,400	6,400	▲700	113.3%
		Livalo	S	600	1,500	2,100	3,900	2,000	2,100	4,100	+200	95.2%
	Glucose metabolic	Fastic	S	2,700	2,700	5,400	5,500	2,700	2,600	5,300	▲200	▲1.9%
	Infection	Cravit	D	20,800	26,300	47,100	50,200	23,600	26,600	50,200	+0	6.6%
		Carbenin	S	4,000	3,800	7,800	6,900	3,400	2,900	6,300	▲600	▲19.2%
		Banan	S	2,600	3,000	5,600	4,800	2,000	2,400	4,400	▲400	▲21.4%
	Cancer	Topotecin	D	1,800	2,100	3,900	5,000	2,500	2,300	4,800	▲200	23.1%
	Immunological allergic	Zyrtec	D	4,200	7,200	11,400	11,600	5,600	7,000	12,600	+1,000	10.5%
	Bone/Joint	Loxonin	S	14,000	14,600	28,600	28,700	14,300	14,700	29,000	+300	1.4%
		Mobic	D	3,800	4,700	8,500	10,800	5,400	5,200	10,600	▲200	24.7%
		Miltax	D	3,100	2,800	5,900	6,100	3,100	2,900	6,000	▲100	1.7%
	Others	Omnipaque	D	17,900	16,300	34,200	34,100	18,000	16,700	34,700	+600	1.5%
Kremezin		S	7,100	6,500	13,600	13,200	6,600	6,400	13,000	▲200	▲4.4%	
Zantac		S	4,400	4,100	8,500	7,500	3,900	3,500	7,400	▲100	▲12.9%	
Omniscan		D	2,600	2,500	5,100	5,400	2,800	2,600	5,400	+0	5.9%	
Evoxac		D	600	600	1,200	1,400	700	600	1,300	▲100	8.3%	
Exports	Pravastatin		S	43,200	33,800	77,000	59,700	38,600	25,900	64,500	+4,800	▲16.2%
	Levofloxacin		D	13,200	11,000	24,200	29,200	14,900	14,600	29,500	+300	21.9%
**Overseas	S P I	Benicar/Benicar HCT (mil \$)	S	13,600 (125)	16,700 (155)	30,300 (280)	47,700 (443)	22,800 (215)	27,500 (241)	50,300 (456)	+2,600 +13	66.0% 62.9%
		WelChol (mil \$)	S	6,700 (61)	5,900 (55)	12,600 (116)	14,000 (130)	7,400 (69)	7,400 (65)	14,800 (134)	+800 +4	17.5% 15.5%
	D P C	Floxin Otic (mil \$)	D	2,900 (26)	4,700 (44)	7,600 (71)	8,200 (77)	4,500 (40)	3,600 (31)	8,100 (71)	▲100 ▲6	6.6% ±0.0%
		Evoxac (mil \$)	D	1,000 (9)	1,300 (13)	2,300 (22)	2,900 (27)	1,200 (10)	1,600 (15)	2,800 (25)	▲100 ▲2	21.7% 13.6%
	L P I	Venofer (mil \$)	S	9,300 (86)	10,100 (94)	19,400 (180)	21,000 (195)	10,300 (97)	12,300 (108)	22,600 (205)	+1,600 +10	16.5% 13.9%
		S P G	Olmotec (mil EURO)	S	2,100 (15)	3,700 (28)	5,800 (43)	14,900 (109)	7,200 (53)	7,500 (54)	14,700 (107)	▲200 ▲2
			Mevalotin (mil EURO)	S	6,200 (46)	4,200 (32)	10,400 (78)	5,100 (38)	2,400 (18)	3,100 (22)	5,500 (40)	+400 +2

* Sales company 【S : Sankyo、D : Daiichi Pharmaceuticals】

** Accounting term of overseas subsidiaries(SPI,LPI,SPG) is from January to December.

◇Exchange rate 【Daiichi Pharmaceuticals】 1\$=standard(actual)

1 \$ =	105	105	105	105	105	105	105
	(108.25)	(104.49)	(106.45)		(108.58)	(115.99)	(112.28)

◇Exchange rate (SPI:Sankyo Pharma Inc., LPI: Luitpold Pharmaceuticals Inc., SPG:Sankyo Pharma GmbH)

1 \$ =	108.50	-	108.23	107.83	106.10	-	110.21
1 EURO =	133.17	-	134.47	136.08	136.26	-	136.92

◇Exchange rate (DPC:Daiichi Pharmaceutical Corporation)

1 \$ =	109.59	-	107.38		109.64	-	113.40
--------	--------	---	--------	--	--------	---	--------

Main Prescription drug sales

			2006 Estimate					
			1st half		2nd half	Whole Year		
				Change			Change	
Japan	Cardiovascular	Mevalotin	S	34,500	▲10.4%	33,700	68,200	▲9.3%
		Panaldine	D	10,600	▲27.9%	9,100	19,700	▲30.4%
		Artist	D	9,200	1.1%	9,600	18,800	3.3%
		Sunrhythm	D	5,600	▲6.7%	5,700	11,300	▲5.0%
		Acecol	S	3,600	▲25.0%	3,700	7,300	▲19.8%
		Olmotec	S	16,800	68.0%	18,600	35,400	38.3%
		Coversyl	D	3,600	▲20.0%	3,500	7,100	▲15.5%
		Hanp	D	4,000	2.6%	5,200	9,200	7.0%
		Calblock	S	4,300	43.3%	4,900	9,200	43.8%
		Livalo	S	2,500	25.0%	3,100	5,600	36.6%
	Glucose metabolic	Fastic	S	2,800	3.7%	2,900	5,700	7.5%
	Infection	Cravit	D	21,900	▲7.2%	25,700	47,600	▲5.2%
		Carbenin	S	3,300	▲2.9%	3,100	6,400	1.6%
		Banan	S	2,100	5.0%	2,100	4,200	▲4.5%
	Cancer	Topotecin	D	2,650	6.0%	2,900	5,550	15.6%
	Immunological allergic	Zyrtec	D	5,150	▲8.0%	6,100	11,250	▲10.7%
	Bone/Joint	Loxonin	S	14,100	▲1.4%	14,400	28,500	▲1.7%
		Mobic	D	5,500	1.9%	5,600	11,100	4.7%
		Miltax	D	2,900	▲6.5%	2,600	5,500	▲8.3%
	Others	Omnipaque	D	15,500	▲13.9%	14,100	29,600	▲14.7%
Kremezin		S	6,100	▲7.6%	6,300	12,400	▲4.6%	
Zantac		S	3,400	▲12.8%	3,200	6,600	▲10.8%	
Omniscan		D	2,600	▲7.1%	2,500	5,100	▲5.6%	
Evoxac		D	700	±0.0%	750	1,450	11.5%	
Exports	Pravastatin		S	10,200	▲73.6%	9,000	19,200	▲70.2%
	Levofloxacin		D	15,300	2.7%	15,000	30,300	2.7%
Overseas	D S I *	Benicar/Benicar HCT		50,400	121.1%	36,600	87,000	73.0%
		(mil \$)		(438)	103.7%	(319)	(757)	66.0%
		WelChol		12,300	66.2%	8,400	20,700	39.9%
		(mil \$)		(107)	55.1%	(73)	(180)	34.3%
		Floxin Otic***		4,000	25.4%	3,800	7,800	26.5%
	L P I ***	(mil \$)		(34)	17.2%	(33)	(67)	24.1%
		Evoxac***		1,300	34.0%	1,400	2,700	12.3%
		(mil \$)		(11)	25.0%	(12)	(23)	9.5%
	S P G	Venofer		19,000	84.5%	8,200	27,200	20.4%
		(mil \$)		(166)	71.1%	(70)	(236)	15.1%
Olmotec		9,500	31.9%	11,100	20,600	40.1%		
(mil EURO)		(70)	32.1%	(82)	(152)	42.1%		
Mevalotin		2,500	4.2%	2,700	5,200	▲5.5%		
(mil EURO)		(18)	±0.0%	(22)	(40)	±0.0%		

* Sales company 【S : Sankyo, D : Daiichi Pharmaceuticals】

** DSI and LPI fiscal year covering 15 months.

*** Sales of Froxin Otic and Evoxac is chaged from Gross sales to Net sales.

◇Exchange rate 【Daiichi Pharmaceuticals】 1\$=standard(actual)

1 \$ = 115 115

◇Exchange rate 【Overseass subsidiaries】

1 \$ = 115 115

1 EURO = 135 135

Consolidated sales of Global Products 【Actual】

(million yen)

	FY2004			FY2005					
	1st half	2nd half	Full Year	Estimate (November 2005)	1st half	2nd half	Full Year		
							Difference from estimate	Change	
Olmesartan	20,300	25,300	45,600	88,300	41,100	51,300	92,400	+4,100	102.6%
Japan : Olmetec	4,500	4,500	9,000	24,000	10,100	15,500	25,600	+1,600	184.4%
U.S:Benicar	13,600	16,700	30,300	47,700	22,800	27,500	50,300	+2,600	66.0%
Europe:Olmetec	2,100	3,700	5,800	14,900	7,200	7,500	14,700	▲200	153.4%
Others	100	400	500	1,700	1,100	700	1,800	+100	260.0%
Lovofloxin	41,700	48,600	90,300	95,800	46,600	51,000	97,600	+1,800	8.1%
Japan : Cravit	20,800	26,300	47,100	50,200	23,600	26,600	50,200	+0	6.6%
Exports	13,200	11,000	24,200	29,200	14,900	14,600	29,500	+300	21.9%
Royalty	7,700	11,300	19,000	16,400	8,100	9,800	17,900	+1,500	▲5.8%
Pravastatin	90,100	76,600	166,700	140,100	79,200	64,000	143,200	+3,100	▲14.1%
Japan:Mevalotin	42,600	39,900	82,500	75,900	38,500	36,700	75,200	▲700	▲8.8%
Europe	6,200	4,200	10,400	5,100	2,400	3,100	5,500	+400	▲47.1%
Exports	41,300	32,500	73,800	59,100	38,300	24,200	62,500	+3,400	▲15.3%

OTC drug sales

(million yen)

	FY2004			FY2005					
	1st half	2nd half	Full Year	Estimate (November 2005)	1st half	2nd half	Full Year		
							Difference from estimate	Change	
Total	15,500	14,100	29,600	30,800	14,700	13,100	27,900	▲2,900	▲5.7%
LuLu series	4,200	4,400	8,600	9,600	4,700	4,700	9,400	▲200	9.3%
Shin-sankyo Ichoyaku series	1,500	1,500	3,000	3,400	1,600	1,700	3,300	▲100	10.0%
Karoyan series	2,400	1,400	3,800	2,700	1,100	1,000	2,100	▲600	▲44.7%
Regain series	1,300	1,050	2,350	2,600	1,400	990	2,390	▲210	1.7%
Patecs series	1,100	1,000	2,100	2,200	1,100	900	2,000	▲200	▲4.8%
Lamisil AT	1,100	1,000	2,100	2,200	1,100	1,500	2,600	+400	23.8%

Consolidated sales of Global Products 【Forecast】

	2006 Estimate				
	1st half		2nd half	Full Year	
		Change			Change
Olmesartan	77,900	89.5%	67,400	145,300	57.3%
Japan : Olmetec	16,800	66.3%	18,600	35,400	38.3%
U.S.A:Benicar	50,400	121.1%	36,600	87,000	73.0%
Europe:Olmetec	9,500	31.9%	11,100	20,600	40.1%
Others	1,200	9.1%	1,100	2,300	27.8%
Lovofloxin	45,800	▲1.7%	50,100	95,900	▲1.7%
Japan : Cravit	21,900	▲7.2%	25,700	47,600	▲5.2%
Exports	15,500	4.0%	14,800	30,300	2.7%
Royalty	8,400	3.7%	9,600	18,000	0.6%
Pravastatin	47,000	▲40.7%	45,000	92,000	▲35.8%
Japan:Mevalotin	34,500	▲10.4%	33,700	68,200	▲9.3%
Europe	2,500	4.2%	2,700	5,200	▲5.5%
Exports	10,000	▲73.9%	8,600	18,600	▲70.2%

OTC drug sales

	2006 Estimate				
	1st half		2nd half	Full Year	
		Change			Change
Total	26,000	176.9%	28,200	54,200	94.3%
LuLu series	5,100	8.5%	5,100	10,200	8.5%
Shin-sankyo Ichoyaku series	1,500	▲6.3%	1,500	3,000	▲9.1%
Karoyan series	1,200	9.1%	1,200	2,400	14.3%
Regain series	1,500	7.1%	1,000	2,500	4.6%
Patecs series	1,000	▲9.1%	1,300	2,300	15.0%
Lamisl AT	1,400	27.3%	1,100	2,500	▲3.8%
Gaster 10	2,000	-	2,200	4,200	-
Precol	1,000	-	1,500	2,500	-
Cakonal	800	-	1,200	2,000	-
Makiron	1,200	-	600	1,800	-

Sankyo Group - 34 company					
Company name	Country	Established	Paid-in-capital	Equity owned by	
Principle activities			(thousands)	the parent company(%)	

Company name	Country	Established	Paid-in-capital	Equity owned by	
Principle activities			(thousands)	the parent company(%)	
Wakodo Co., Ltd. Manufacturing and marketing of baby food and milk products	Japan	1953	¥2,918,000	61.2	
Nihon Shoni Iji Shuppansya Co., Ltd. Publishing	Japan	1951	¥20,000	Wakodo 100.0	
Wako Logistics Co., Ltd. Transport, warehousing and packaging	Japan	1951	¥21,000	Wakodo 100.0	
Wako Food Industry Co., Ltd. Manufacturing and marketing of milk products	Japan	1937	¥25,000	Wakodo 100.0	
Fuji Flour Milling Co., Ltd. Manufacturing and marketing of flour, bran, flour mixes and dried noodles	Japan	1941	¥500,000	66.4	
Sankyo Organic Chemicals Co., Ltd. Manufacturing and marketing of pharmaceuticals; commissioned processing and packaging	Japan	1940	¥300,000	93.4	
Nippon Nyukazai Co., Ltd. Manufacturing and marketing of surface-active agents and fine chemicals	Japan	1953	¥300,000	100.0	
Sankyo Chemical Industries, Ltd. Manufacturing and marketing of fine chemicals, pharmaceuticals and its intermediates	Japan	1954	¥65,000	100.0	
Hokkai Sankyo Co., Ltd. Manufacturing and marketing of agrochemicals	Japan	1951	¥331,000	80.0	
Meguro Chemical Industry Co., Ltd. Commissioned processing and packaging of food, pharmaceuticals, cosmetics	Japan	1954	¥40,000	100.0	
Institute of Science and Technology, Inc. Laboratory and biological assay of biogenic specimens and its commissioned business	Japan	1984	¥20,000	100.0	
Sankyo Yell Yakuhin Co., Ltd. Manufacturing and marketing of pharmaceuticals, veterinary drugs, diagnostics	Japan	1932	¥96,000	100.0	
Sankyo Agro Co., Ltd. Manufacturing and marketing and exporting and importing of agrochemicals	Japan	2003	¥350,000	100.0	
Utsunoiya Chemical Industry Co., Ltd. Commissioned processing of agrochemicals	Japan	1951	¥20,000	Sankyo Agro 100.0	
Sankyo Lifetech Co., Ltd. Manufacturing and marketing and exporting and importing of veterinary drugs and food additives	Japan	2003	¥300,000	100.0	
DAIICHI SANKYO HEALTHCARE CO., LTD. Manufacture and sales of drugs, cosmetics, medical devices, food and beverage, among others	Japan	2005	¥10,000	Sankyo 50.0 Daiichi 50.0	
Sankyo Grundstucks GmbH Management of real estate	Germany	1990	Euro5,100	100.0	
Sankyo Grundstucks GmbH & Co. Object Munnich KG Management of real estate	Germany	1990	Euro38,200	Sankyo Grundstucks 94.0	
Sankyo Pharma GmbH (SPG) Development, manufacturing and marketing of pharmaceuticals	Germany	1990	Euro16,000	100.0	
Sankyo Pharma UK Ltd. Marketing of pharmaceuticals	UK	1986	£ 19,500	SPG 100.0	
Sankyo Pharma Espana S.A. Marketing of pharmaceuticals	Spain	1964	Euro120	SPG 100.0	
Sankyo Pharma Italia S.p.A. Marketing of pharmaceuticals	Italy	1970	Euro120	SPG 100.0	
Sankyo Pharma Portugal Lda. Marketing of pharmaceuticals	Portugal	1985	Euro349	SPG 100.0	
Sankyo Pharmazeutika Austria GmbH Marketing of pharmaceuticals	Austria	1994	Euro18	SPG 100.0	
Sankyo Pharma (Schweiz) AG Marketing of pharmaceuticals	Switzerland	1970	CHF3,000	SPG 100.0	
Sankyo Pharma Nederland B.V. Marketing of pharmaceuticals	Holland	1997	Euro18	SPG 100.0	
N.V. Sankyo Pharma Belgium S.A. Marketing of pharmaceuticals	Belgium	1997	Euro62	SPG 100.0	
Oy Sankyo Pharma Finland Ab Marketing of pharmaceuticals	Finland	1996	Euro25	SPG 100.0	
Sankyo Manufacturing France S.A.R.L. Manufacturing of pharmaceuticals	France	1974	Euro457	SPG 100.0	
Dignos-Chemie GmbH Marketing of pharmaceuticals	Germany	1965	Euro40	SPG 100.0	
Sankyo Pharma France S.A.S. Marketing of pharmaceuticals	France	2002	Euro2,182	SPG 100.0	
DAIICHSANKYO INC. Research, development, and marketing of pharmaceuticals	U.S.A	2006	US\$24,900	Sankyo 80.8 Daiichi 19.2	
Luitpold Pharmaceuticals Inc. Manufacturing and marketing of pharmaceuticals and veterinary	U.S.A	1946	US\$200	SPI 100.0	
Sino-Japan Chemical Co., Ltd. Manufacturing, marketing, exporting and importing of emulsifier and surface-active agents	Taiwan	1970	NT\$144,000	52.0	

Daiichi Pharmaceutical Group - 21 Companies				
--	--	--	--	--

Company name Principle activities	Country	Established	Paid-in-capital (thousands)	Equity owned by the parent company(%)
Daiichi Pure Chemicals Co., Ltd. Manufacture and sale of pharmaceuticals and diagnostic reagents	Japan	1947	¥1,275,000	100.0
Daiichi Radioisotope Laboratories, Ltd.(DRL) Manufacture and sale of radiopharmaceuticals and radioisotope products	Japan	1968	¥1,400,000	100.0
Daiichi Pharmatech Co., Ltd.(DPK) Manufacture of pharmaceuticals	Japan	2004	¥100,000	100.0
Daiichi Fine Chemical Co., Ltd. (DFK) Manufacture and sale of pharmaceuticals and fine chemicals	Japan	1951	¥2,276,000	100.0
Daiichi Fine Chemical Europe GmbH (DFE) Sale of fine chemicals and related products	Germany	1989	EUR511	DFK 100.0
Saitama Daiichi Pharmaceutical Co., Ltd. Manufacture and sale of pharmaceuticals	Japan	1963	¥1,005,500	100.0
Daiichi Asubio Pharma(ASB) * Daiichi Suntory Pharma Co., Ltd. (before October 2005) Research, development, manufacture, and marketing of pharmaceuticals	Japan	2002	¥11,000,000	100.0
Daiichi Asubio Pharmaceuticals, Inc.(ASBI) Clinical development of pharmaceuticals	USA	1999	US\$0.001	ASB 100.0
Daiichi Asubio Holdings, Inc.(ASBH) Holding company of DAIAMED	USA	1999	US \$ 6,000	ASB 100.0
Daiichi Asubio Medical Research Laboratories LLC(DAIAMED) Exploratory Research of pharmaceuticals	USA	2000	US\$6,272	ASBH 100.0
Daiichi Estate Co., Ltd. Real estate and travel agency services	Japan	1956	¥100,000	100.0
Daiichi Butsuryu Co., Ltd. Logistics services	Japan	1965	¥50,000	100.0
D. P. C. Medical Co., Ltd. Supply and planning of sales promotional materials	Japan	1995	¥50,000	100.0
Kanto Daiichi Service Co., Ltd. Security and maintenance services	Japan	1979	¥10,000	100.0
Daiichi Pharmaceuticals UK Ltd.(DPL) Sale and clinical development of pharmaceuticals	UK	1993	£400	100.0
Daiichi Pharmaceutical (Beijing) Co., Ltd.(DPP) Manufacture and sale of pharmaceuticals	China	1998	US\$63,800	100.0
Daiichi Pharmaceutical Asia Ltd. (DPA) Sales promotional services for pharmaceuticals	Hong Kong	1988	HK\$3,000	100.0
Daiichi Pharmaceutical Taiwan Ltd.(TDS) Manufacture and sale of pharmaceuticals	Taiwan	1963	NT\$80,000	100.0
Daiichi Pharmaceutical Korea Co., Ltd.(KDP) Sale of pharmaceuticals	Korea	1990	W3,000,000	70.0
Daiichi Pharmaceutical (Thailand) Ltd.(DPT) Sale of pharmaceuticals and fine chemicals	Thailand	1994	Baht10,000	100.0
Laboratoires Daiichi Sanofi-Synthelabo(LDS) Clinical development of pharmaceuticals	France	1989	EUR154	51.0

Sankyo Co., Ltd. (non-consolidated)【Actual】

million yen

	FY2004				Forecast (Nov.)	FY2005				Differenc e from Forecast	Change vs. FY04
	1st half	2nd half	Full year			1st half	2nd half	Full year			
	<-9.7>					<-6.5>					
Net sales	174,817	165,274	100.0	340,091	308,000	163,656	154,471	100.0	318,127	+10,127	▲21,964
Cost of Sales	48,327	46,019	27.7	94,346	81,000	41,551	40,064	25.7	81,615	+615	▲12,731
SG&A	85,470	95,833	53.3	181,303	181,000	88,363	101,804	59.8	190,167	+9,167	+8,864
R&D expenses	34,988	40,064	22.1	75,052	76,000	35,664	50,247	27.0	85,911	+9,911	+10,859
	<-30.6>					<-28.1>					
Operating income	41,019	23,422	18.9	64,441	46,000	33,741	12,603	14.6	46,344	+344	▲18,097
Non-operating income	4,446	2,109	1.9	6,555	4,500	2,930	2,684	1.8	5,614	+1,114	▲941
Non-operating expenses	1,927	4,944	2.0	6,871	3,500	1,549	1,453	0.9	3,002	▲498	▲3,869
	<-31.7>					<-23.7>					
Ordinary income	43,538	20,586	18.9	64,124	47,000	35,122	13,833	15.4	48,955	+1,955	▲15,169
Extraordinary income	15,081	1,791	5.0	16,872	3,000	543	2,864	1.1	3,407	+407	▲13,465
Extraordinary losses	3,608	16,291	5.9	19,899	9,000	8,002	7,953	5.0	15,955	+6,955	▲3,944
Current payable taxes etc.	20,326	3,223	6.9	23,549	19,000	9,755	3,507	4.2	13,262	▲5,738	▲10,287
	<-33.2>					<-38.4>					
Net income	34,683	2,865	11.0	37,548	22,000	17,907	5,238	7.3	23,145	+1,145	▲14,403

Daiichi Pharmaceutical Co., Ltd. (non-consolidated)【Actual】

million yen

	FY2004				Forecast (Nov.)	FY2005				Differenc e from Forecast	Change vs. FY04
	1st half	2nd half	Full year			1st half	2nd half	Full year			
	<2.5>					<7.0>					
Net sales	126,222	133,690	100.0	259,912	267,000	132,313	145,880	100.0	278,193	+11,193	+18,281
Cost of Sales	40,164	41,840	31.6	82,004	78,700	38,650	39,791	28.2	78,441	▲259	▲3,563
SG&A	61,940	61,527	47.5	123,467	131,300	64,080	64,701	46.3	128,781	▲2,519	+5,314
R&D expenses	21,935	20,763	16.4	42,698	47,400	22,832	23,904	16.8	46,736	▲664	+4,038
	<20.0>					<30.7>					
Operating income	24,117	30,323	20.9	54,440	57,000	29,582	41,592	25.6	71,174	+14,174	+16,734
Non-operating income	1,762	1,167	3.6	2,929	4,200	2,327	1,970	5.5	4,297	+97	+1,368
Non-operating expenses	274	772	0.8	1,046	1,200	553	757	1.0	1,310	+110	+264
	<21.1>					<31.7>					
Ordinary income	25,605	30,717	21.7	56,322	60,000	31,356	42,804	26.7	74,160	+14,160	+17,838
Extraordinary income	679	14,842	6.0	15,521	900	847	17	0.3	864	▲36	▲14,657
Extraordinary losses	7,619	19,359	10.4	26,978	16,900	13,387	4,345	6.4	17,732	+832	▲9,246
Current payable taxes etc.	7,580	17,981	9.8	25,561	22,000	11,353	14,740	9.4	26,093	+4,093	+532
	<-31.1>					<61.6>					
Net income	11,085	8,218	7.4	19,303	22,000	7,462	23,737	11.2	31,199	+9,199	+11,896

Sankyo Pharma Inc.【Actual/\$】

million yen

	FY2004				FY2005				Difference from Forecast	Change vs. FY04	
	1st half	2nd half	Full year		Forecast (Nov.)	1st half	2nd half	Full year			
Net sales	201,610	225,312	<60.6> 100.0 426,922		609,297	302,238	328,876	<47.8> 100.0 631,114		+21,817	+204,192
Cost of Sales	41,075	39,242	18.8	80,317	120,192	56,886	65,094	19.3	121,980	+1,788	+41,663
SG&A	161,268	212,943	87.7	374,211	480,295	211,621	239,019	71.4	450,640	▲29,655	+76,429
R&D expenses	19,130	24,890	10.3	44,020	80,620	33,661	23,803	9.1	57,464	▲23,156	+13,444
Operating income	-733	-26,873	<-73.2> -6.5 -27,606		8,810	33,731	24,763	<-> 9.3 58,494		+49,684	+86,100
Non-operating income and expenses	15,991	2,219	4.3	18,210	21,400	-1,874	19,731	2.8	17,857	▲3,543	▲353
Ordinary income	15,258	-24,654	<-89.3> -2.2 -9,396		30,210	31,857	44,494	<-> 12.1 76,351		+46,141	+85,747
Extraordinary income	0	0	0.0	0	0	0	0	0.0	0	+0	+0
Extraordinary losses	5	-1	0.0	4	0	0	6,172	1.0	6,172	+6,172	+6,168
Current payable taxes etc.	-22,281	-23,017	-10.6	-45,298	-49,948	-21,339	-5,232	-4.2	-26,571	+23,377	+18,727
Net income	37,534	-1,636	<-128.8> 8.4 35,898		80,158	53,196	43,554	<169.5> 15.3 96,750		+16,592	+60,852
Benicar/Benicar HCT	125,553	154,869	<146.2>	280,422	443,082	215,291	241,099	<62.8>	456,390	+13,308	+175,968
WelChol	61,939	55,053	<-3.2>	116,992	130,151	69,790	64,675	<14.9>	134,465	+4,314	+17,473
Exchange rate 1\$=	108.50			108.23	107.83	106.10			110.21		

Daiichi Pharma Holdings, Inc.【Actual/\$】

million yen

	FY2004				FY2005				Difference from Forecast	Change vs. FY04	
	1st half	2nd half	Full year		Forecast (Nov.)	1st half	2nd half	Full year			
Net sales	64,867	85,664	<7.4> 100.0 150,531		213,040	96,470	105,866	<34.4> 100.0 202,336		▲10,704	+51,805
Cost of Sales	5,353	7,572	8.6	12,925	12,355	6,127	6,309	8.6	12,436	+81	▲489
SG&A	65,797	77,859	65.1	143,656	101,701	90,244	91,923	65.1	182,167	+80,466	+38,511
R&D expenses	17,667	27,960	30.3	45,627	97,319	39,894	44,767	41.8	84,661	▲12,658	+39,034
Operating income	-6,283	233	-6.5	-6,050	1,666	100	7,634	3.8	7,734	+6,068	+13,784
Non-operating income and expenses	-257	16	4.3	-241	1,761	157	103	0.1	260	▲1,501	+501
Ordinary income	-6,026	217	-2.2	-5,809	-95	-57	7,530	3.7	7,473	+7,568	+13,282
Extraordinary income	159	-43	0.0	116	0	0	0	0.0	0	+0	▲116
Extraordinary losses	0	0	0.0	0	0	7,212	44,628	25.6	51,840	+51,840	+51,840
Current payable taxes etc.	-1,761	6,713	-10.6	4,952	40	40	804	0.4	844	+804	▲4,108
Net income	-4,106	-6,539	8.4	-10,645	-135	-7,309	-37,902	-22.3	-45,211	▲45,076	▲34,566
Floxinotic	26,239	44,357	<-14.0>	70,596	76,536	40,717	30,861	<1.4>	71,578	▲4,958	+982
Evoxac	8,747	12,990	<38.2>	21,737	26,903	10,946	14,123	<15.3>	25,069	▲1,834	+3,332
Exchange rate 1\$=	110			107	105	110			113		

Sankyo Pharma Inc.【Actual/YEN】

million yen

	FY2004				FY2005					Difference from Forecast	Change vs. FY04	
	1st half	2nd half	Full year		Forecast (Nov.)	1st half	2nd half	Full year				
	<49.8>					<50.5>						
Net sales	21,874	24,331	100.0	46,205	65,700	32,067	37,488	100.0	69,555	+3,855	+23,350	
Cost of Sales	4,456	4,236	18.8	8,692	12,900	6,035	7,408	19.3	13,443	+543	+4,751	
SG&A	17,497	23,003	87.7	40,500	51,700	22,452	27,213	71.4	49,665	▲2,035	+9,165	
R&D expenses	2,075	2,689	10.3	4,764	8,600	3,571	2,762	9.1	6,333	▲2,267	+1,569	
Operating income	-79	-2,908	-6.5	-2,987	900	3,578	2,868	9.3	6,446	+5,546	+9,433	
Non-operating income and expenses	1,735	235	4.3	1,970	2,300	-198	2,166	2.8	1,968	▲332	▲2	
Ordinary income	1,655	-2,672	-2.2	-1,017	3,200	3,380	5,034	12.1	8,414	+5,214	+9,431	
Extraordinary income	0	0	0.0	0	0	0	0	0.0	0	+0	+0	
Extraordinary losses	0	0	0.0	0	0	0	680	1.0	680	+680	+680	
Current payable taxes etc.	-2,417	-2,485	-10.6	-4,902	-5,400	-2,264	-664	-4.2	-2,928	+2,472	+1,974	
Net income	4,072	-187	8.4	3,885	8,600	5,644	5,018	15.3	10,662	+2,062	+6,777	
	<-75.0>					<->						
Benicar/Benicar HCT	13,623	16,727	<129.7>	30,350	47,700	22,843	27,455	<65.7>	50,298	+2,598	+19,948	
WelChol	6,720	5,942	<-9.7>	12,662	14,000	7,405	7,414	<17.0>	14,819	+819	+2,157	

Sales Division

Net sales	20,342	22,801	<57.5>	43,143	61,900	30,319	34,952	<51.3>	65,271	+3,371	+22,128
Operating income	425	-2,207	<-91.4>	-1,782	5,200	5,303	2,652	<->	7,955	+2,755	+9,737
Operating income before Royalty deduction	1,739	-584	<-105.9>	1,155	9,900	7,537	5,602	<1,037.6>	13,139	+3,239	+11,984

Daiichi Pharma Holdings, Inc.【Actual/YEN】

million yen

	FY2004				FY2005					Difference from Forecast	Change vs. FY04	
	1st half	2nd half	Full year		Forecast (Nov.)	1st half	2nd half	Full year				
	<1.9>					<42.0>						
Net sales	7,109	9,055	100.0	16,164	22,817	10,577	12,368	100.0	22,945	+128	+6,781	
Cost of Sales	587	801	8.6	1,388	1,326	672	738	6.1	1,410	+84	+22	
SG&A	7,211	8,215	95.4	15,426	21,316	9,894	10,763	90.0	20,658	▲658	+5,232	
R&D expenses	1,936	2,963	30.3	4,899	10,404	4,374	5,227	41.8	9,601	▲803	+4,701	
Operating income	-689	39	-4.0	-650	175	11	866	3.8	877	+702	+1,527	
Non-operating income and expenses	-28	2	-0.2	-26	186	17	12	0.1	29	▲157	+55	
Ordinary income	-660	37	-3.9	-624	-10	-6	854	3.7	847	+857	+1,471	
Extraordinary income	17	-5	0.1	12	0	0	0	0.0	0	+0	▲12	
Extraordinary losses	0	0	0.0	0	※ 0	791	5,088	25.6	5,879	+5,879	+5,879	
Current payable taxes etc.	-193	725	3.3	532	4	4	91	0.4	96	+92	▲436	
Net income	-450	-693	-7.1	-1,143	-15	-801	-4,326	-22.3	-5,127	▲5,112	▲3,984	
	<-18.4>					<7.1>						
Floxinotic	2,876	4,705	<-18.4>	7,581	8,225	4,464	3,653	<7.1>	8,117	▲108	+536	
Evoxic	959	1,376	<31.1>	2,334	2,876	1,200	1,643	<21.8>	2,843	▲33	+509	

Luitpold Pharmaceuticals Inc.【Actual/\$】

million \$

	FY2004				Forecast (Nov.)	FY2005				Difference from Forecast	Change vs. FY04
	1st half	2nd half	Full year			1st half	2nd half	Full year			
	<17.8>					<14.4>					
Net sales	151,754	161,477	100.0	313,231	336,775	169,563	188,852	100.0	358,415	+21,640	+45,184
Cost of Sales	43,971	45,090	28.4	89,061	112,297	53,592	57,634	31.0	111,226	▲1,071	+22,165
SG&A	35,798	40,341	24.3	76,139	69,649	34,863	44,693	22.2	79,556	+9,907	+3,417
R&D expenses	5,210	9,618	4.7	14,828	18,126	8,163	16,205	6.8	24,368	+6,242	+9,540
	<-243.5>					<13.2>					
Operating income	71,985	76,046	47.3	148,031	154,829	81,108	86,525	46.8	167,633	+12,804	+19,602
Non-operating income and expenses	1,243	2,446	1.2	3,689	9,700	4,266	6,602	3.0	10,868	+1,168	+7,179
	<-273.3>					<17.7>					
Ordinary income	73,228	78,492	48.4	151,720	164,529	85,374	93,127	49.8	178,501	+13,972	+26,781
Extraordinary income	23	0	0.0	23	0	2	0	0.0	2	+2	▲21
Extraordinary losses	3	29	0.0	32	0	14	0	0.0	14	+14	▲18
Current payable taxes etc.	26,756	27,757	17.4	54,513	56,307	25,670	28,698	15.2	54,368	▲1,939	▲145
	<-178.0>					<27.7>					
Net income	46,492	50,706	31.0	97,198	108,222	59,692	64,429	34.6	124,121	+15,899	+26,923
Venofor	86,056	94,025	<21.8>	180,081	195,402	97,497	107,559	<13.9>	205,056	+9,654	+24,975
Exchange rate 1\$=	108.50			108.23	107.83	106.10			110.21		

Sankyo Pharma GmbH【Actual/EURO】

million Euro

	FY2004				Forecast (Nov.)	FY2005				Difference from Forecast	Change vs. FY04
	1st half	2nd half	Full year			1st half	2nd half	Full year			
	<45.3>					<-0.7>					
Net sales	157,894	194,643	100.0	352,537	332,660	163,905	186,134	100.0	350,039	+17,379	▲2,498
Cost of Sales	64,126	55,551	33.9	119,677	95,048	48,669	48,356	27.7	97,025	+1,977	▲22,652
SG&A	114,243	129,687	69.2	243,930	268,490	128,091	128,238	73.2	256,329	▲12,161	+12,399
R&D expenses	16,129	14,121	8.6	30,250	35,540	15,723	8,308	6.9	24,031	▲11,509	▲6,219
	<-77.5>					<->					
Operating income	-20,475	9,405	-3.1	-11,070	-30,878	-12,855	9,540	-0.9	-3,315	+27,563	+7,755
Non-operating income and expenses	1,813	4,715	1.9	6,528	5,710	2,965	1,193	1.2	4,158	▲1,552	▲2,370
	<-90.7>					<->					
Ordinary income	-18,662	14,120	-1.3	-4,542	-25,168	-9,890	10,733	0.2	843	+26,011	+5,385
Extraordinary income	35	195	0.1	230	8	8	218	0.1	226	+218	▲4
Extraordinary losses	6	202	0.1	208	180	180	311	0.1	491	+311	+283
Current payable taxes etc.	347	844	0.3	1,191	631	312	-111	0.1	201	▲430	▲990
	<-88.6>					<->					
Net income	-18,980	13,269	-1.6	-5,711	-25,971	-10,374	10,751	0.1	377	+26,348	+6,088
Olmotec	15,732	27,911	<130.0>	43,643	109,824	53,228	54,417	<146.6>	107,645	▲2,179	+64,002
Pravastatin	46,605	31,405	<20.0>	78,010	37,966	17,984	22,257	<-48.4>	40,241	+2,275	▲37,769
Cefpodxime	8,552	12,760	<38.3>	21,312	22,364	13,228	11,617	<16.6>	24,845	+2,481	+3,533
Exchange rate 1\$=	133.17			134.47	136.08	136.26			136.92		

Luitpold Pharmaceuticals Inc.【Actual/YEN】

million yen

	FY2004				Forecast (Nov.)	FY2005				Difference from Forecast	Change vs. FY04
	1st half	2nd half	Full year			1st half	2nd half	Full year			
			<1.0>					<16.5>			
Net sales	16,465	17,435	100.0	33,900	36,300	17,990	21,510	100.0	39,500	+3,200	+5,600
Cost of Sales	4,770	4,869	28.4	9,639	12,100	5,686	6,572	31.0	12,258	+158	+2,619
SG&A	3,884	4,354	24.3	8,238	7,500	3,698	5,069	22.2	8,767	+1,267	+529
R&D expenses	565	1,039	4.7	1,604	1,900	866	1,819	6.8	2,685	+785	+1,081
Operating income	7,810	8,213	47.3	16,023	16,600	8,605	9,869	46.8	18,474	+1,874	+2,451
Non-operating income and expenses	134	265	1.2	399	1,100	452	746	3.0	1,198	+98	+799
Ordinary income	7,945	8,477	48.4	16,422	17,700	9,058	10,614	49.8	19,672	+1,972	+3,250
Extraordinary income	2	0	0.0	2	0	0	0	0.0	0	+0	▲2
Extraordinary losses	0	3	0.0	3	1	1	0	0.0	1	+0	▲2
Current payable taxes etc.	2,903	2,996	17.4	5,899	6,029	2,723	3,268	15.2	5,991	▲38	+92
Net income	5,044	5,478	31.0	10,522	11,670	6,333	7,346	34.6	13,679	+2,009	+3,157
			<19.7>					<30.0>			
Venofer	9,337	10,153	<13.6>	19,490	21,000	10,344	12,255	<16.0>	22,599	+1,599	+3,109

Sankyo Pharma GmbH【Actual/YEN】

million yen

	FY2004				Forecast (Nov.)	FY2005				Difference from Forecast	Change vs. FY04
	1st half	2nd half	Full year			1st half	2nd half	Full year			
			<49.1>					<1.1>			
Net sales	21,026	26,378	100.0	47,404	45,200	22,333	25,594	100.0	47,927	+2,727	+523
Cost of Sales	8,539	7,553	33.9	16,092	12,900	6,631	6,653	27.7	13,284	+384	▲2,808
SG&A	15,213	17,586	69.2	32,799	36,500	17,453	17,643	73.2	35,096	▲1,404	+2,297
R&D expenses	2,147	1,920	8.6	4,067	4,800	2,142	1,148	6.9	3,290	▲1,510	▲777
Operating income	-2,726	1,239	-3.1	-1,487	-4,200	-1,751	1,298	-0.9	-453	+3,747	+1,034
Non-operating income and expenses	241	637	1.9	878	800	404	165	1.2	569	▲231	▲309
Ordinary income	-2,485	1,876	-1.3	-609	-3,400	-1,347	1,462	0.2	115	+3,515	+724
Extraordinary income	4	26	0.1	30	1	1	29	0.1	30	+29	+0
Extraordinary losses	0	27	0.1	27	24	24	43	0.1	67	+43	+40
Current payable taxes etc.	46	114	0.3	160	77	42	-15	0.1	27	▲50	▲133
Net income	-2,527	1,761	-1.6	-766	-3,500	-1,413	1,464	0.1	51	+3,551	+817
			<-88.3>					0 <->			
Olmetec	2,095	3,774	<136.1>	5,869	14,900	7,252	7,486	<151.1>	14,738	▲162	+8,869
Pravastatin	6,206	4,284	<23.2>	10,490	5,100	2,450	3,059	<-47.5>	5,509	+409	▲4,981
Cefpodxime	1,139	1,727	<42.0>	2,866	3,000	1,802	1,599	<18.7>	3,401	+401	+535

Sales Division

Net sales	20,623	26,044	<51.1>	46,667	44,600	22,027	24,777	<0.3>	46,804	+2,204	+137
Operating income	-2,333	1,494	<-85.3>	-839	-1,400	-745	1,351	<->	606	+2,006	+1,445
Operating income before Royalty deduction	-1,979	2,034	<-101.1>	55	500	240	2,457	<4,803.6>	2,697	+2,197	+2,642

Daiichi-Sankyo Group Research & Development Pipeline (1)

Therapeutic Area	Development Code Number	Generic Name	Dosage Form/Route	Indication/Class	Origin
Cardiovascular diseases	CS-747	Prasugrel	Oral	Acute coronary syndrome / Anti-platelet agent	Sankyo, Ube Industries
	—	Hepatocyte growth factor DNA plasmid	Injection	Peripheral arterial diseases, Coronary arterial diseases / Vascular regeneration therapy by HGF-DNA	AnGes MG (Sales agreement)
	DU-176b	—	Oral	Atrial fibrillation, Venous thromboembolism / Oral factor Xa inhibitor	Daiichi
	CS-9803	—	Injection	Acute myocardial infarction / Delta PKC inhibitor	KAI pharmaceuticals
	☆CS-8663	Olmesartan medoxomil, Amlodipine besilate	Oral	Hypertension / Angiotensin II receptor antagonist, Calcium blocker	Sankyo
	☆CS-866DM	Olmesartan medoxomil	Oral	Diabetic nephropathy / Angiotensin II receptor antagonist	Sankyo
	☆CS-866RN	Olmesartan medoxomil	Oral	Chronic glomerulonephritis / Angiotensin II receptor antagonist	Sankyo
	☆CS-866AZ	Olmesartan medoxomil, Azelnidipine	Oral	Hypertension / Angiotensin II receptor antagonist, Calcium blocker	Sankyo
	☆CS-866CMB	Olmesartan medoxomil, Hydrochlorothiazide	Oral	Hypertension / Angiotensin II receptor antagonist, Diuretic	Sankyo
	SUN 4936h	Carperitide (Recombinant)	Injection	Acute heart failure / α -human atrial natriuretic peptide	Daiichi Asubio
Glucose metabolic disorders	CS-011	Rivoglitazone	Oral	Diabetes / Glitazone agent that improves insulin resistance	Sankyo
	CS-917	—	Oral	Diabetes / Gluconeogenesis inhibitor	Sankyo, Metabasis
	☆WeiChol DM	Colesevelam hydrochloride	Oral	Diabetes	Genzyme

☆additional indications, new formulations etc.

May 2006
DAIICHI SANKYO CO., LTD.

Region	Developer	Stage	Comments
US/EU	Sankyo, Eli Lilly	P-III	<ul style="list-style-type: none"> In nonclinical trials, this antithrombotic drug exhibited stronger activity in inhibiting platelet aggregation and faster manifestation of activity compared to other drugs. In clinical trials, it was confirmed that there were few differences among individuals in the inhibition of platelet aggregation. Co-development with Eli Lilly in the US and Europe
Japan	Sankyo	P-I	
US/EU	AnGes MG	P-II (PAD)	Intramuscular injection of HGF-DNA in the diseased area generates hepatocyte growth hormone, which induces regeneration of blood vessels in patients with peripheral arterial diseases (PAD), e.g. arteriosclerotic obliteration, Buerger's disease, or coronary arterial diseases (CAD), e.g. cardiac infarction and angina pectoris. Daiichi obtained exclusive marketing rights in Japan, the US and Europe, and will fully support development by AnGes MG and will contribute to the international development of regenerative medicine.
		P-I (CAD)	
Japan		P-III (PAD)	
		P-I Preparation (CAD)	
US/EU	Daiichi	P-II	<ul style="list-style-type: none"> An anticoagulant possessing anti-Xa activity, with confirmed high oral absorption within human trials.
Japan	Daiichi	P-II	
US/EU	Sankyo, KAI pharmaceuticals	P-I / II	Delta PKC inhibitor, is expected to be a first in class agent for reduction of reperfusion injury in acute myocardial infarction patients undergoing revascularization procedures.
US/EU	Sankyo	P-III	Olmesartan/Ca channel blocker (Amlodipine) combination
Japan	Sankyo	P-III	<ul style="list-style-type: none"> ORIENT trials are underway Additional indication
Japan	Sankyo	P-II	Additional indication
Japan	Sankyo	P-II	Olmesartan/Ca channel blocker (Azelnidipine) combination
Japan	Sankyo	P-II	<ul style="list-style-type: none"> Launch : USA 03/09, EU 05/06 Olmesartan/diuretic (Hydrochlorothiazide) combination
US/EU	Astellas US	P-II	<ul style="list-style-type: none"> Carperitide is an α-human atrial natriuretic peptide which has both vasodilating and diuretic activity. Since approval of HANP(Brand Name) in 1995 in Japan, its sales have been steadily growing and is now playing a central role in the treatment of acute heart failure. Licensed-out to Astellas US in the US and Europe
US/EU	Sankyo	P-II	<ul style="list-style-type: none"> A new glitazone type antidiabetic drug which exhibits strong PPAR γ activity. In clinical trial, dose-dependent efficacy on plasma glucose and lipid parameters superior to other agents were demonstrated.
Japan	Sankyo	P-I Preparation	
US/EU	Sankyo	P-II	An antidiabetic drug which blocks fructose-1,6-biphosphate which is an enzyme which governs gluconeogenesis in the liver.
US	Sankyo	P-III	<ul style="list-style-type: none"> Additional indication This drug is anticipated to be a supplement to diet and exercise therapy for type-2 diabetes patients where ordinary treatment is found to be ineffective. In clinical trial, HbA1c level decrease was confirmed in diabetic patients on insulin.

【project after Phase II】

Daiichi-Sankyo Group Research & Development Pipeline (2)

Therapeutic Area	Development Code Number	Generic Name	Dosage Form/Route	Indication/Class	Origin
Infectious diseases	DF-098	<i>Haemophilus influenzae</i> type b conjugate vaccine	Injection	Prevention of <i>Haemophilus influenzae</i> type b invasive infections	Sanofi Pasteur (Sales agreement with joint venture)
	DU-6859a	Sitafloxacin hydrate	Injection	New quinolone	Daiichi
			Oral		
	CS-023	—	Injection	Antibiotic (Carbapenem type)	Sankyo
SUN A0026	Faropenem medoxomil	Oral	Antibiotic (Penem type)	Daiichi Asubio	
Cancer	DJ-927	—	Oral, Injection	Cancer chemotherapeutic (Taxane deriv.)	Daiichi
Immunological allergic diseases	CS-712	—	Oral	Cedar pollen pollinosis / Oral immune desensitization	Sankyo
Bone/Joint diseases	CS-706	—	Oral	Anti-inflammatory and analgesic	Sankyo
	☆CS-600G	Loxoprofen sodium	Gel	Anti-inflammatory and analgesic	Sankyo
	SUN E3001	(Trivial Name) Human parathyroid hormone [hPTH]	Nasal Spray (Liquid type)	Osteoporosis	Daiichi Asubio
Others	DD-723	—	Injection	Ultrasound contrast media	GE Healthcare
	SUN Y7017	Memantine hydrochloride	Oral	Dementia of Alzheimer type / NMDA receptor antagonist	Merz
	SUN N4057	—	Injection	Acute Ischemic Stroke / Serotonin (5-HT) 1A receptor agonist	Daiichi Asubio
	KMD-3213	Silodosin	Oral	Treatment of dysuria associated with benign prostatic hyperplasia / Selective alpha 1A blocker	Kissei
	CS-088	Olmesartan	Eyedrops	Glaucoma / Angiotensin II receptor antagonist	Sankyo
	☆DL-8234	Interferon-β	Injection	Hepatitis C (with Ribavirin)	Toray
	☆CS-1401E	Fentanyl citrate	Injection	Pain relief during anesthesia	Janssen
	SUN0588r	Sapropterin hydrochloride (Tetrahydrobiopterin)	Oral	Hyperphenylalaninemia	Daiichi Asubio




☆additional indications, new formulations etc.

May 2006

Region	Developer	Stage	Comments
Japan	Sanofi Pasteur – Daiichi Vaccines	Application (03.3)	<i>Haemophilus influenzae</i> type b conjugate vaccine useful for the prevention of bacterial meningitis in children. Introduced from Sanofi Pasteur and developed and filed for approval by joint venture Sanofi Pasteur–Daiichi Vaccines.
US	Daiichi	P–II	<ul style="list-style-type: none"> •A next-generation new quinolone agent with broad-spectrum and potent antibacterial activity, expected to be also effective for severe infections. •In Japan, clinical trials are underway for the development of an oral formulation to treat respiratory tract infection and urinary tract infection. •In the US, clinical trials are underway for the development of an injectable formulation to treat severe infectious diseases.
Japan	Daiichi	P–III	
US/EU	Roche	P–II	<ul style="list-style-type: none"> •A carbapenem antibiotic possessing strong activity and a broad antibacterial spectrum targeting various pathogenic bacteria including drug resistant bacterium. •Licensed-out to Roche in the US and Eupore
Japan	Sankyo	P–II	
North America	Replidyne	Application (05.12)	<ul style="list-style-type: none"> •Faropenem medoxomil is a prodrug of Faropenem sodium, the first oral penem-type antibiotic launched in 1997 in Japan. It is orally active and well absorbed through the gastro-intestinal tract, and rapidly converted to Faropenem. It is effective against various pathogenic bacteria, including the problematic antibiotic-resistant bacteria, PRSP (penicillin-resistant <i>Streptococcus pneumoniae</i>). •Licensed-out to Replidyne in North America, and Replidyne and Forest entered into an agreement for the commercialization.
US/EU	Daiichi	P–II	<ul style="list-style-type: none"> •A taxane derivative anti-cancer agent available for oral administration. •Shows a broader anti-tumor spectrum than the existing agents in the same class (docetaxel, paclitaxel), as well as reduced neurological toxicity in nonclinical trials.
Japan	Daiichi	P–I	
Japan	Sankyo	P–II	Technical collaboration with Hayashibara Biochemical Laboratories
US/EU	Sankyo	P–II	<ul style="list-style-type: none"> •COX-2 inhibitor •The results of PK/PD trial suggested administration once per day.
Japan	Sankyo	P–III Preparation	<ul style="list-style-type: none"> •Loxoprofen gel •Formulation by TOKO YAKUHIN KOGYO
Japan	Chugai	P–II	<ul style="list-style-type: none"> •PTH is a novel anti-osteoporosis drug that stimulates bone formation, in contrast to major current drugs on the market which possess anti-bone resorption activity. The self-injection type of hPTH(1-34) is marketed in the US and EU. •Licensed-out to Chugai in Japan
Japan	Daiichi	Application (04.5)	<ul style="list-style-type: none"> •An ultrasound contrast medium for diagnosis of the liver. •Intravenous administration of the medium enables detection of liver tumors at bedside.
Japan	Daiichi Asubio	(Mild to moderate) P–III (Moderately severe to severe) P–III	Memantine, categorized as an antagonist of the NMDA receptor which is one of the Glutamate receptor subtypes in the central nervous system in mammals, possesses therapeutic action for dementia of Alzheimer type. The drug is expected to demonstrate effectivity in slowing down the progression of the disease by its neuroprotective action, which is distinct from cholinesterase inhibitors. The phase III trial for moderately severe to severe dementia of Alzheimer type and for mild to moderate dementia of Alzheimer type is on-going.
US/EU	Daiichi Asubio	P–II	SUN N4057 is a neuroprotective agent that increases cerebral inhibitory neurotransmission via activation of serotonin (5-HT) 1A receptors. SUN N4057 can inhibit ischemic neuronal death and is expected to minimize infarction size during the acute stage and improve prognosis in acute stroke patients.
China	Daiichi	P–II	<ul style="list-style-type: none"> •An alpha1A blocker which effectively reduces urinary tract resistance and improves dysuria associated with benign prostatic hyperplasia. •Reduces cardiovascular side effects due to its alpha1A selectivity.
US/EU	Santen, Sankyo	P–II	••Co-development with Santen in Japan, the US and Europe
Japan		P–II	
Japan	Daiichi, Toray	P–III	<ul style="list-style-type: none"> •A natural interferon-beta preparation with reduced adverse reactions, such as depression and alopecia, in comparison with interferon-alpha. •The agent is undergoing clinical trial as an additional indication for targeting hepatitis C with ribavirin.
Japan	–	P–III	<ul style="list-style-type: none"> •Doctor-initiated investigation. •Expanded adaptation of the opioid analgesic fentanyl citrate (Brand Name:Fentanest) toward infants (directions for use and dosage).
US/EU	BioMarin	P–III	<ul style="list-style-type: none"> •Biopren was approved in Japan as an etiologic therapeutic agent to treat atypical hyperphenylalaninemia (an inherited metabolic disease caused by BH4 deficiency) in 1992. Recent clinical investigations indicated that a subgroup of hyperphenylalaninemia, caused by phenylalaninehydroxylase(PAH) deficiency, responded to BH4. •Licensed-out to BioMarin outside Japan

【project after Phase II】

Daiichi Sankyo Group Research & Development Pipeline (Development Stage)

Therapeutic Area	Main Existing Product	Phase1 preparation, preclinical	Phase1
Cardiovascular diseases	Pravachol / Mevalotin Benicar / Olmetec Welchol MEVALOTIN Panaldine Artist ACECOL Sunrythm Coversyl OLMETEC HANP CALBLOCK LIVALO CAPTORIL Slonnon	DZ-697b(JP) (anti-platelet agent) HGF DNA therapy(JP) (coronary arterial diseases) CS-3030(US/EU) (oral factor Xa inhibitor)	CS-747(JP) (anti-platelet agent) DZ-697b(US/EU) (anti-platelet agent) HGF DNA therapy(US/EU) (coronary arterial diseases) 
Glucose metabolic disorders	FASTIC	CS-011(JP) (antidiabetic/glitazone type)	SUN E7001(JP) (GLP-1)
Infectious diseases	LEVAQUIN / Tavanic FROXIN Otic BANAN Cravit CARBENIN BANAN	DC-159a(US/EU/JP) (new quinolone) DX-619(JP) (new quinolone) CS-8958(JP) (anti-influenza)	DX-619(US/EU) (new quinolone) CS-758(US/EU) (azole antifungal) CS-8958(US/EU) (anti-influenza)
Cancer	camptoser Topotecin KRESTIN	CS-1008(US/EU) (anti-DR5 antibody)	DJ-927(JP) (anti-cancer/oral taxane deriv.) CS-7017(US/EU) (PPAR γ activator)
Immunological allergic diseases	Zyrtec	DW-908e(JP) (VLA-4 inhibitor) 	DW-908e(US/EU) (VLA-4 inhibitor) CS-0777(US/EU) (immunomodulator)
Bone/Joint diseases	LOXONIN Mobic Miltax	OCIF(US/EU) (osteoporosis)	
Others	Venofer Evoxac Omnipaque KREMEZIN ZANTAC Omniscan FERON KELNAC Neuer Evoxac Adenoscan	SUN N8075(JP) (acute ischemic stroke) CS-011(JP) (dry eye/licensed-out to Santen) 	SUN N8075(US/EU) (acute ischemic stroke) SUN11031(JP) (anorexia nervosa) SUN11031(US/EU) (cachexia)

★additional indications, new formulations etc.

□ Change of Stage(change from the announcement in the R&D meeting of March 2006)
: CS-866AZ(JP), CS-0777(US/EU), SUN11031(US/EU)

May 2006
DAIICHI SANKYO CO., LTD.

Phase2	Phase3	Application/Approval, Launch
DU-176b(US/EU/JP)(oral factor Xa inhibitor) HGF DNA therapy(US/EU) (peripheral arterial diseases) CS-9803(US/EU)(delta PKC inhibitor) SUN 4936h(US/EU)(acute heart failure/ licensed-out to Astellas US) ☆CS-866RN(JP)(chronic glomerulonephritis) ☆CS-866CMB(JP) (Olmesartan/Hydrochlorotiazide combination) ☆CS-866AZ(JP) (Olmesartan/Azelnidipine combination)	CS-747(US/EU) (anti-platelet agent) ☆CS-8663(US/EU) (Olmesartan/Amlodipine combination) HGF DNA therapy(JP) (peripheral arterial diseases) ☆CS-866DM(JP) (diabetic nephropathy)	
CS-011(US/EU) (antidiabetic/glitazone type) CS-917(US/EU) (gluconeogenesis inhibitor)	☆WeiChol DM(US) (antidiabetic)	
DU-6859a inj(US) (new quinolone) CS-023(US/EU) (carbapenem-type antibiotic/ licensed-out to Roche) CS-023(JP) (carbapenem-type antibiotic)	DU-6859a oral(JP) (new quinolone)	SUN A0026(North America) (penem-type antibiotic/ licensed-out to Replidyne/ application) DF-098(JP) (Hib vaccine/application)
DJ-927(US/EU) (anti-cancer/oral taxane deriv.)		
CS-712(JP) (cedar pollen pollinosis)		
CS-706(US/EU) (COX-2 inhibitor) SUN E3001(JP) (osteoporosis/licensed-out to Chugai)	☆CS-600G(JP) (loxoprofen gel/P3 preparation)	☆LOXONIN PAP (JP) (loxoprofen patch/approval)
SUN N4057(US/EU) (acute ischemic stroke) CS-088(US/EU/JP) (antiglaucoma/co-development with Santen) KMD-3213(China) (treatment of dysuria associated with benign prostatic hyperplasia)	SUN0588r(US) (hyperphenylalaninemia/ licensed-out to Biomarin) SUN Y7017(JP) (mild to moderate and severe dementia of Alzheimer type) ☆DL-8234(JP) (FERON add indic./ hepatitis/with Ribavirin) ☆CS-1401E(JP) (pain relief during anesthesia)	Intrathecal Gabalon (JP) (anti-spastic/launch) URIEF(JP) (treatment of dysuria/launch) ☆FERON(JP) (liver cirrhosis/approval) DD-723(JP) (ultrasound contrast media/application)



The forecasts and other figures included in these materials are derived from our assessments and assumptions based on information available and are subject to risks and uncertainties. Actual earnings may differ from these forecast values.